Overview of Clinical Results
Totality of data provides convincing evidence of efficacy for tegaserod 12 mg/d on global relief measure and secondary parameters of efficacy
Favorable benefit-to-risk profile in constipation-predominant IBS, a disorder with no proven therapeutic options